Non-Hodgkin Lymphoma Flashcards
The earliest IHC marker for B-lineage differentiation.
CD19
Acquired late in pre-B-cell stage of maturation; lost at the plasma cell stage.
CD20
Strongly positive: half of lymphoblastic lymphoma/leukemia; all mature B-cell lymphomas; Reedsternberg cells in 1/4 cases of HL
CD20: cytoplasmic staining
IHC marker found in follicular dendritic cells and some B lymphocytes; helps identify the hyperplastic islands of dendritic cells in angioimmunoblastic T-cell lymphoma.
CD21
IHC marker strongly expressed in hairy cell leukemia.
CD22
IHC marker that is most useful in distinguishing B-cell CLL/SLL from other entities and remains present in CLL/SLL that has undergone large cell transformation.
CD23
Expressed in nearly all of the assayed precursor B-cell lymphoblastic lymphoma/leukemias, with no T-cell staining. Also positive in mature B-cell lymphomas.
CD79a
Strongly stains the cytoplasm of most hairy cell leukemias, marginal zone lymphomas, and large cell lymphomas
DBA.44
Normal lymph node: CD79a positive as marker for early B-cell antigen
Mantle zone
Most germinal centers
Scattered interfollicular zone
Normal lymph node: CD2 positive areas as marker for early T-cell antigen.
Most interfollicular lymphocytes as well as scattered in light zone of germinal center
IHC marker for early T-cell antigen in a normal lymph node.
CD2
Positive with most T-cell lymphomas except anaplastic large cell lymphomas and NK leukemias/lymphomas. Very specific for T-cell derivation.
CD3 (cell membrane)
It interacts with HLA class II during antigen recognition, and defines a helper-inducer subset of T cells. Expressed in most mature T-cell lymphomas.
CD4
Detectable on the surface of most thymocytes and immature peripheral T cells and in a small subset of circulating B cells. Primarily used in the detection of B cell CLL/SLL and mantle cell lymphoma.
CD5
It has the distinction of being the most frequently lost T-subset marker in malignancies, particularly on mycosis fungiodes.
CD7
Also present on non-T-cell malignancies, including NK tumors and AML
CD7